Chronic Inflammatory Demyelinating Polyneuropathy - 26 Studies Found
| Completed |
: Evaluate Efficacy and Safety of Fingolimod 0.5 mg Orally Once Daily Versus Placebo in Chronic Inflammatory Demyelinating Polyradiculoneuropathy Patients. : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2012-06-19 :
|
| Completed |
: Safety and Efficacy of Avonex in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2004-12-15 : Drug: Interferon Beta-1a |
| Completed |
: Effect of Resistance and Aerobic Exercise in CIDP or MMN :
|
| Withdrawn |
: Pilot Study of Acthar® Gel in Chronic Inflammatory Demyelinating Neuropathy : Chronic Inflammatory Demyelinating Polyneuropathy : 2015-08-30 : Drug: H.P. Acthar® Gel Other Names:
|
| Not yet recruiting |
: Exploratory Study of Predictive Markers of the Therapeutic Response in Patients With Chronic Inflammatory Demyelinating Polyradiculoneuropathy Treated With Intravenous Immunoglobulin : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2016-08-29 :
|
| Completed |
: MRI in Diagnosing and Monitoring CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2013-12-06 |
| Recruiting |
: Efficacy and Safety Study of I10E in Treatment of Patients With CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2014-11-13 : Drug: I10E Patients who meet all eligibility criteria will |
| Recruiting |
: Efficacy and Safety Study of I10E in the Maintenance Treatment of Patients With CIDP: Extension of PRISM Study I10E-1302 : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2014-12-11 : Drug: I10E Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 4 |
| Recruiting |
: Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2016-11-02 : Biological: HYQVIA Other Names:
|
| Recruiting |
: Phase III Efficacy, Safety, and Tolerability Study of HYQVIA/HyQvia and GAMMAGARD LIQUID/KIOVIG in CIDP : Chronic Inflammatory Demyelinating Polyradiculoneuropathy : 2015-09-11 :
|